Patent intelligence · EP
EP 2491925
Antitumorigene Kombinaton, die Cabazitaxel und Cisplatin umfasst
Antitumorigene Kombinaton, die Cabazitaxel und Cisplatin umfasst
Patent details — EP 2491925
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Aug 29, 2012
- Expiration
- Aug 24, 2032
- Applicant
- AVENTIS PHARMA SA [FR]
- CPC classes
- A61K 31/ 337 A I, A61K 33/ 243 A I, A61K/31337, A61K/33243
Quick answer
EP 2491925 (Antitumorigene Kombinaton, die Cabazitaxel und Cisplatin umfasst) is held by AVENTIS PHARMA SA [FR]. Status: granted. Granted Aug 29, 2012. Expires Aug 24, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AVENTIS PHARMA SA [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 337 A I, A61K 33/ 243 A I, A61K/31337, A61K/33243, A61P 35/ 00 A I, A61P/3500
More from AVENTIS PHARMA SA [FR]
Related pharmaceutical patents in our USPTO index.
-
EP 3093014
CABAZITAXEL UND DESSEN VERWENDUNG ZUR BEHANDLUNG VON KREBS
granted -
WO 2015104417
UTILISATION DU CABAZITAXEL POUR LE TRAITEMENT DE L'ADÉNOCARCINOME GASTRIQUE
granted -
WO 2015036507
UTILISATION DE CABAZITAXEL CHEZ DES PATIENTS CHEZ QUI UN CANCER DU POUMON NON À PETITES CELLULES MÉTASTATIQUE CONTINUE À PROGRESSER APRÈS UN TRAITEMENT À BASE DE DOCÉTAXEL
granted -
CA 2903132
CABAZITAXEL ET SON UTILISATION POUR LE TRAITEMENT DES CANCERS DE LA PROSTATE METASTATIQUES
granted -
EP 2678011
ANTITUMORIGENE KOMBINATON, DIE CABAZITAXEL UND CISPLATIN UMFASST
granted -
EP 2656851
Semuloparin zur Verbesserung der Überlebenschance von Krebspatienten
granted -
CA 2864029
NOUVELLES UTILISATIONS PEDIATRIQUES DU CABAZITAXEL
granted -
EP 2620148
Antitumorkombination mit Cabazitaxel und Cisplatin
granted
Frequently asked questions
What is US patent 2491925?
EP 2491925 (Antitumorigene Kombinaton, die Cabazitaxel und Cisplatin umfasst) is held by AVENTIS PHARMA SA [FR]. Status: granted. Granted Aug 29, 2012. Expires Aug 24, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2491925?
AVENTIS PHARMA SA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 2491925 expire?
Our index shows an expiration date of Aug 24, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.